TLSI · TriSalus Life Sciences, Inc.
$4.15
-0.16 (-3.71%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$267.23M
Shares
61.57M
Volume · Oct 1
273.18K
Avg daily vol (3M)
288.7K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.15
Open$4.27
Day$4.02–4.27
52W close$2.52–7.50
Avg vol 30d356K
Short int3.3M · 5.4% float · 28.8d
Short vol73%
Last earningsAug 6, 2026
DataFeb 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$45.08M
Trailing 12 months
Net income (TTM)
−$28.21M
Trailing 12 months
Revenue growth YoY
+1.7%
Year over year
Operating margin
-67.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13.22M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+77.2%
Year over year · more shares
Price change (1Y)
-7.3%
Trailing year
Short interest
5.4%
Latest settlement · 28.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. TriSalus reported Q2 2026 revenue of $11.4 million (up 1.7% year-over-year) and reiterated full-year 2026 revenue guidance of $54–$57 million, while announcing a new CMS G-code extending TriNav reimbursement into office-based labs. Gross margin expanded to 86.8%, but adjusted EBITDA loss widened to $7.1 million and sales and marketing expense jumped to $11.4 million on commercial expansion.
Bullish
- + CMS established a new G-code extending TriNav reimbursement into the office-based lab setting, expanding the addressable site of care.
- + Gross margin expanded 290 basis points year-over-year to 86.8% on lower unit costs and manufacturing improvements.
- + Management expects sequential revenue improvement from Q2 to Q3 and stronger Q4, with sales and marketing expense declining in the second half.
- + Cash of $46.3 million is described as fully funding the strategic growth plan.
Bearish
- − Adjusted EBITDA loss widened to $7.1 million from $5.3 million on elevated commercial investment.
- − Operating loss widened to $9.8 million from $7.3 million year-over-year.
- − TriNav Advance 510(k) FDA review is running past the MDUFA goal date, creating near-term uncertainty on launch timing.
- − Pancreatic program strategy is under review due to changes in the treatment landscape, delaying forward visibility.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
−15%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
33%
mid-range
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−2%
trailing
YTD return
−41%
this year
Relative strength
−14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-9% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.43% of float · ▼ -9.4% MoM · 28.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+53%
Y/Y
Gross margin
85%
contracting
EPS growth
−40%
Y/Y
Free cash flow
$-18.9M
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Full-year 2026 revenue
· full-year 2026
Initiated
$54M – $57M
prior FY $45.15M
midpoint +22.9% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
33%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $5 — 50d above 200d
Institutional flow
Distributing
-9% holders QoQ · +11 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.43% of float · ▼ -9.4% MoM · 28.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
82 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 33%
Range high $8
vs 200-day avg -12%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$12.87M | Six Months Ended June 30, 2026 | — |
| EBITDA | -$5.06M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TLSI
this stock
TriSalus Life Sciences, Inc.
|
$267.23M | -40.5% | +53.4% | — | 5.4% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.8% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.0% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -22.3% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -54.7% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TLSI | -10.0% | -19.3% | -1.7% | -3.7% | -40.5% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -9.6% | -19.1% | -14.1% | -3.9% | -52.6% |